News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Will Sovaldi, Drive Gilead Sciences, Inc. (GILD) To The Top Of The Biopharm Industry?


3/25/2014 8:13:18 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Gilead has been making a lot of headlines lately with its new drug for hepatitis C, Sovaldi. This is an interferon-free oral drug that eliminates this virus in a large number of patients. This alone would be notable, but Gilead is going one step better. It is developing a combination of Sovaldi with another of its drugs, GS-5816 and this promises to cure all types of hepatitis C with a single pill. This has been the dream of anti-viral researchers for decades.

Help employers find you! Check out all the jobs and post your resume.

Read more at Forbes.

comments powered by Disqus

Read at Forbes

comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES